ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression

Pharmacogenetics and Genomics - Tập 27 Số 12 - Trang 454-463 - 2017
Rachel J. Eclov1, Mee J. Kim2, Aparna Chhibber1, Robin P. Smith2, Nadav Ahituv2, Deanna L. Kroetz2
1Department of Bioengineering and Therapeutic Sciences
2Department of Bioengineering and Therapeutic Sciences; Institute for Human Genetics, University of California San Francisco, San Francisco, California, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Robey, 2009, ABCG2: a perspective, Adv Drug Deliv Rev, 61, 3, 10.1016/j.addr.2008.11.003

Jonker, 2002, The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria, Proc Natl Acad Sci USA, 99, 15649, 10.1073/pnas.202607599

Reginato, 2012, The genetics of hyperuricaemia and gout, Nat Rev Rheumatol, 8, 610, 10.1038/nrrheum.2012.144

Cusatis, 2006, Pharmacogenetics of ABCG2 and adverse reactions to gefitinib, J Natl Cancer Inst, 98, 1739, 10.1093/jnci/djj469

Yoh, 2004, Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer, Clin Cancer Res, 10, 1691, 10.1158/1078-0432.CCR-0937-3

Noguchi, 2009, Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy, Adv Drug Deliv Rev, 61, 26, 10.1016/j.addr.2008.07.003

Tsunoda, 2006, ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma, Oncology, 71, 251, 10.1159/000106787

Usuda, 2010, Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer, Lung Cancer, 67, 198, 10.1016/j.lungcan.2009.04.002

Mao, 2015, Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update, AAPS J, 17, 65, 10.1208/s12248-014-9668-6

Poonkuzhali, 2008, Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms, Drug Metab Dispos, 36, 780, 10.1124/dmd.107.018366

Georgitsi, 2011, Transcriptional regulation and pharmacogenomics, Pharmacogenomics, 12, 655, 10.2217/pgs.10.215

Smith, 2012, Pharmacogene regulatory elements: from discovery to applications, Genome Med, 4, 45, 10.1186/gm344

Ge, 2009, Global patterns of cis variation in human cells revealed by high-density allelic expression analysis, Nat Genet, 41, 1216, 10.1038/ng.473

Pastinen, 2010, Genome-wide allele-specific analysis: insights into regulatory variation, Nat Rev Genet, 11, 533, 10.1038/nrg2815

Eclov, 2017, In vivo hepatic enhancer elements in the human ABCG2 locus, Drug Metab Dispos, 45, 208, 10.1124/dmd.116.072033

Abecasis, 2012, An integrated map of genetic variation from 1,092 human genomes, Nature, 491, 56, 10.1038/nature11632

Frazer, 2007, A second generation human haplotype map of over 3.1 million SNPs, Nature, 449, 851, 10.1038/nature06258

Johnson, 2008, SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap, Bioinformatics, 24, 2938, 10.1093/bioinformatics/btn564

Barrett, 2005, Haploview: analysis and visualization of LD and haplotype maps, Bioinformatics, 21, 263, 10.1093/bioinformatics/bth457

Liu, 2008, An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol, BMC Biotechnol, 8, 91, 10.1186/1472-6750-8-91

Simonet, 1993, A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice, J Biol Chem, 268, 8221, 10.1016/S0021-9258(18)53085-4

Kim, 2013, The hydrodynamic tail vein assay as a tool for the study of liver promoters and enhancers, Methods Mol Biol, 1015, 279, 10.1007/978-1-62703-435-7_18

Kim, 2011, Functional characterization of liver enhancers that regulate drug-associated transporters, Clin Pharmacol Ther, 89, 571, 10.1038/clpt.2010.353

Kroetz, 2010, The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology, Clin Pharmacol Ther, 87, 109, 10.1038/clpt.2009.226

Bolstad, 2003, A comparison of normalization methods for high density oligonucleotide array data based on variance and bias, Bioinformatics, 19, 185, 10.1093/bioinformatics/19.2.185

Boes, 2005, Normalization for Affymetrix GeneChips, Methods Inf Med, 44, 414, 10.1055/s-0038-1633986

Schadt, 2008, Mapping the genetic architecture of gene expression in human liver, Plos Biol, 6, e107, 10.1371/journal.pbio.0060107

2012, Comprehensive molecular portraits of human breast tumours., Nature, 490, 61, 10.1038/nature11412

Yang, 2010, Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies, Bioinformatics, 26, 2474, 10.1093/bioinformatics/btq452

Nica, 2011, The architecture of gene regulatory variation across multiple human tissues: the MuTHER study, PLoS Genet, 7, e1002003, 10.1371/journal.pgen.1002003

Grundberg, 2012, Mapping cis- and trans-regulatory effects across multiple tissues in twins, Nat Genet, 44, 1084, 10.1038/ng.2394

Stranger, 2007, Population genomics of human gene expression, Nat Genet, 39, 1217, 10.1038/ng2142

Stranger, 2005, Genome-wide associations of gene expression variation in humans, PLoS Genet, 1, e78, 10.1371/journal.pgen.0010078

Stranger, 2007, Relative impact of nucleotide and copy number variation on gene expression phenotypes, Science, 315, 848, 10.1126/science.1136678

Stranger, 2012, Patterns of cis regulatory variation in diverse human populations, PLoS Genet, 8, e1002639, 10.1371/journal.pgen.1002639

Dimas, 2009, Common regulatory variation impacts gene expression in a cell type-dependent manner, Science, 325, 1246, 10.1126/science.1174148

Rudin, 2008, Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity, J Clin Oncol, 26, 1119, 10.1200/JCO.2007.13.1128

Campa, 2012, A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk, Int J Cancer, 131, 803, 10.1002/ijc.26436

McLeod, 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741, J Clin Oncol, 28, 3227, 10.1200/JCO.2009.21.7943

Matsson, 2012, Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping, Pharmacogenomics J, 12, 214, 10.1038/tpj.2011.8

Blazquez, 2012, Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta, Mol Pharmacol, 81, 273, 10.1124/mol.111.075143

Jonker, 2005, The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk, Nat Med, 11, 127, 10.1038/nm1186

Jonker, 2000, Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan, J Natl Cancer Inst, 92, 1651, 10.1093/jnci/92.20.1651

Honorat, 2008, Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells, Biochem Biophys Res Commun, 375, 308, 10.1016/j.bbrc.2008.07.149

Li, 2002, Locus control regions, Blood, 100, 3077, 10.1182/blood-2002-04-1104